Advertisement

International Journal of Hematology

, Volume 108, Issue 2, pp 203–207 | Cite as

Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review

  • Kazuya Sakai
  • Akane Ueda
  • Masaaki Hasegawa
  • Yasunori Ueda
Case Report

Abstract

For pregnant women with essential thrombocythemia (ET), no standard approach for managing the platelet count has been established. We present the cases of two pregnant women with ET treated with interferon (IFN)-alpha. Each case showed a marked platelet decrease, from values within normal limits at the time of delivery, with no severe adverse events. To clarify the efficacy and safely of IFN alpha for ET during pregnancy, we performed a literature review. A total of 43 pregnant women with ET were ultimately identified from 12 articles and the present cases. IFN-alpha therapy decreased platelet counts to normal levels at birth in many cases, and there were no adverse events that required the discontinuation of IFN-alpha treatment. Overall, 93% of pregnant women with ET gave birth to healthy babies. We consider that, given its efficacy and safety, IFN-alpha therapy is a reasonable treatment option for pregnant women with ET.

Keywords

Essential thrombocythemia Pregnancy Prenatal care Interferon alpha Literature review 

Notes

Compliance with ethical standards

Informed consent

Consent to publish this case report was obtained from each patient.

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179–84.CrossRefPubMedGoogle Scholar
  2. 2.
    Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110(2):485–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Melillo L, Tieghi A, Candoni A, Radaelli F, Ciancia R, Specchia G, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry. Am J Hematol. 2009;84(10):636–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Bates SM, Ginsberg JS. Thrombosis in pregnancy. Curr Opin Hematol. 1997;4(5):335–43.CrossRefPubMedGoogle Scholar
  5. 5.
    Asano Y, Okaniwa A. In utero morphological effects of hydroxyurea on the fetal development in Sprague–Dawley rats. Jikken Dobutsu. 1987;36(2):143–9.PubMedGoogle Scholar
  6. 6.
    Chow EY, Haley LP, Vickars LM. Essential thrombocythemia in pregnancy: platelet count and pregnancy outcome. Am J Hematol. 1992;41(4):249–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Pagliaro P, Arrigoni L, Muggiasca ML, Poggio M, Russo U, Rossi E. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. Am J Hematol. 1996;53(1):6–10.CrossRefPubMedGoogle Scholar
  8. 8.
    Finazzi G. How to manage essential thrombocythemia. Leukemia. 2012;26(5):875–82.CrossRefPubMedGoogle Scholar
  9. 9.
    Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Sobas MA, Perez Encinas MM, Rabunal Martinez MJ, Quinteiro Garcia C, Bello Lopez JL. Anagrelide treatment in early pregnancy in a patient with JAK2V617F-positive essential thrombocythemia: case report and literature review. Acta Haematol. 2009;122(4):221–2.CrossRefPubMedGoogle Scholar
  11. 11.
    Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010;149(3):352–75.CrossRefPubMedGoogle Scholar
  12. 12.
    Niittyvuopio R, Juvonen E, Kaaja R, Oksanen K, Hallman H, Timonen T, et al. Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. Eur J Haematol. 2004;73(6):431–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Martinelli P, Martinelli V, Agangi A, Maruotti GM, Paladini D, Ciancia R, et al. Interferon alfa treatment for pregnant women affected by essential thrombocythemia: case reports and a review. Am J Obstet Gynecol. 2004;191(6):2016–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Iwashita T, Fujitani M, Yamamoto Y, Katsurada T, Yoshida Y. Interferon-alfa treatment of essential thrombocythemia during pregnancy. Intern Med. 2006;45(20):1161–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Singh N, Kumar S, Roy KK, Sharma V, Jalak A. Successful maternal and fetal outcome in a rare case of essential thrombocythemia with pregnancy using interferon alpha. Platelets. 2012;23(4):319–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Williams JM, Schlesinger PE, Gray AG. Successful treatment of essential thrombocythaemia and recurrent abortion with alpha interferon. Br J Haematol. 1994;88(3):647–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Shpilberg O, Shimon I, Sofer O, Dolitski M, Ben-Bassat I. Transient normal platelet counts and decreased requirement for interferon during pregnancy in essential thrombocythaemia. Br J Haematol. 1996;92(2):491–3.CrossRefPubMedGoogle Scholar
  18. 18.
    Vianelli N, Gugliotta L, Tura S, Bovicelli L, Rizzo N, Gabrielli A. Interferon-alpha 2a treatment in a pregnant woman with essential thrombocythemia. Blood. 1994;83(3):874–5.PubMedGoogle Scholar
  19. 19.
    Diez-Martin JL, Banas MH, Fernandez MN. Childbearing age patients with essential thrombocythemia: should they be placed on interferon? Am J Hematol. 1996;52:331–2.CrossRefPubMedGoogle Scholar
  20. 20.
    Pulik M, Lionnet F, Genet P, Petitdidier C, Jary L. Platelet counts during pregnancy in essential thrombocythaemia treated with recombinant alpha-interferon. Br J Haematol. 1996;93(2):495.PubMedGoogle Scholar
  21. 21.
    Perez-Encinas M, Bello JL, Perez-Crespo S, De Miguel R, Tome S. Familial myeloproliferative syndrome. Am J Hematol. 1994;46(3):225–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Yoshida Y, Katsurada T, Nakabou Y, Kawabata H. Efficacy of interferon-alpha in essential thrombocythemia during pregnancy. Ann Hematol. 2017;96:877–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol. 2005;129(3):293–306.CrossRefPubMedGoogle Scholar
  24. 24.
    Vantroyen B, Vanstraelen D. Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. Acta Haematol. 2002;107(3):158–69.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  1. 1.Department of Hematology and OncologyKurashiki Central HospitalKurashikiJapan
  2. 2.Department of Obstetrics and GynecologyKurashiki Central HospitalKurashikiJapan

Personalised recommendations